Biogen reported that its oral MS drug, BG-12 (dimethyl fumarate), performed well in its latest pivotal trial and met its goal in reducing MS flare-ups over two years. The drug also met secondary goals of reducing the number of new or enlargin brain lesions and slowing the rate of disability.
BG-12 is on the cusp of joining Biogen's other MS stable-mates, Avonex (interferon B) and Tysabri (natalizumab), to stregthen its industry leading MS franchise. In addition to the benefits cited above, BG-12 was also said to offer a good safety profile and the convenience of taking it orally is considered big plus to patients. Biogen shares were up 5% on the news. See Xconomy.
Posted by Bruce Lehr April 11th 2011.
More on this from Fierce Biotech today (April 11th)http://www.fiercebiotech.com/story/biogen-flags-ph3-success-crucial-ms-drug/2011-04-11?utm_medium=rss&utm_source=rss
Posted by: bigredbruce | 04/11/2011 at 02:55 PM